Chautauqua Rehabilitation and Nursing Center to offer Monoclonal Antibodies for treatment of High Risk Covid-19 Patients


SYRACUSE, NY – VestraCare, an operator of high-quality nursing and rehabilitation facilities, is pleased to announce that its Bishop Rehabilitation and Nursing Center is now offering monoclonal antibody infusions for the treatment of high-risk Covid-19 patients.


In November 2020, the FDA (Food and Drug Administration) issued EUA (emergency use authorization) for the use of monoclonal antibodies for the treatment of high-risk patients with mild to moderate Covid-19 symptoms at risk for progression to severe illness and hospitalization. This is the same treatment that was given to the US President.


Bishop has the advanced clinical setting necessary to administer the infusions, as well as a highly skilled nursing staff and on-site medical providers. “We’re happy to have this important treatment available to care for high-risk patients and provide them with an advanced option to help fight the virus,” stated Administrator Tim Reedy, LNHA.


The clinical team at Bishop has been working closely with its Medical Director, Dr. J. Bishop to implement protocols for administration and aftercare in concert with those specified in the EUA.


The antibodies are made with proteins created in a laboratory and are designed to mimic the antibodies created in the body’s immune system to ward off the virus and fight infection. Bishop will receive the compounded medication from its pharmacy provider, PharmScripts on a per-patient basis.


Residents will receive the treatment in-house in the comfort of a familiar environment. The team at Bishop provides continuous monitoring in a designated area prior, during and post-infusion.


Bishop Rehabilitation and Nursing Center provides 24-hour skilled nursing care, subacute rehabilitation and short-term respite care. For more information, visit


No responses yet

Leave a Reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1 other subscriber